← All Sponsors
SPONSOR

Henan Cancer Hospital

Total Trials
9
Recruiting
9
Phases
Phase 3, Phase 2

Henan Cancer Hospital is a clinical research sponsor with 9 registered studies on ClinicalTrials.gov, of which 9 are actively recruiting participants. Research covers conditions including Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation, Breast Cancer,HER2-positive.

The trial portfolio spans Phase 3, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Henan Cancer Hospital

How many clinical trials has Henan Cancer Hospital sponsored?
ClinicalMetric currently tracks 9 clinical trials sponsored by Henan Cancer Hospital, of which 9 are actively recruiting participants. These trials cover conditions including Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Henan Cancer Hospital research focus on?
Henan Cancer Hospital clinical trials span Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation, Breast Cancer,HER2-positive, Gastric/Gastroesophageal Junction Adenocarcinoma, and additional conditions. The research pipeline includes Phase 3, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Henan Cancer Hospital clinical trial?
To participate in a Henan Cancer Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Henan Cancer Hospital trials with current recruitment status updated daily.

Clinical Trials by Henan Cancer Hospital

NCT06643000
Recruiting

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Non-small Cell Lung Cancer
NCT04547907 Phase 3
Recruiting

A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Breast Cancer,HER2-positive
NCT06774222 Phase 2
Recruiting

A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG

Gastric/Gastroesophageal Junction Adenocarcinoma
NCT05911958 Phase 2
Recruiting

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

HER2 Low Breast Carcinoma
NCT04891016 Phase 2
Recruiting

Toripalimab Plus FLOT in Locally Advanced Gastric Cancer

Chemotherapy
NCT04263935
Recruiting

Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma

Lymphoma
NCT05769010 Phase 2
Recruiting

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

Metastatic Breast Cancer
NCT07244016
Recruiting

Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC

Extensive-stage Small-cell Lung Cancer
NCT06605521
Recruiting

To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients

Locally Advanced Breast Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology